10 Nov 18:35
by Lucas Kambanis,
Joshua J. Dilly,
Joshua W. C. Maxwell,
Skye Stockdale,
Sarah E. Fry,
Katriona Harrison,
Scott N. Byrne,
Anneliese S. Ashhurst,
Sameer S. Kulkarni,
Richard J. Payne
This manuscript describes a powerful semi-synthetic strategy for producing native lipoproteins using peptide selenoesters. Two mycobacterial lipoproteins, LprA and Mpt83, were generated through this method and shown to activate Toll-like receptor 2 and activate immune responses. The aryl selenoester-mediated expressed protein ligation method reported here offers a general platform for generating homogeneous lipoproteins in the future.
Abstract
Tuberculosis (TB), caused by infection with the bacterium Mycobacterium tuberculosis (Mtb), remains one of the most prevalent infectious diseases worldwide. Despite decades of dedicated efforts to develop effective prevention strategies, including vaccines, TB continues to cause significant morbidity and mortality globally. Beyond the Bacille Calmette–Guérin (BCG) vaccine, limited progress has been made to develop more effective TB vaccines. A better understanding of the immunomodulatory roles of key Mtb protein virulence factors is therefore needed for the development of more efficacious protein-based vaccine candidates. Herein, we report a highly efficient method for the semi-synthesis of two native mycobacterial lipoproteins and glycolipoproteins, LprA and Mpt83, respectively. Capitalising on the enhanced reactivity of peptide selenoesters as acyl donors, the 21–23 kDa homogeneously lipidated proteins could be generated in a single ligation step. The homogeneous mycobacterial lipoprotein and glycolipoprotein molecules were shown to be agonists of Toll-like receptor 2 (TLR2) and led to the potent induction of pro-inflammatory cytokines and chemokines in cells. Taken together, this work presents a robust semi-synthetic platform for accessing lipoproteins involved in host–pathogen interactions that can help guide future TB vaccine design.
10 Nov 18:32
by Haowen Zhao,
Etienne Bickel,
Jiaqi Liu,
Xiaoli Yang,
Michael Dal Molin,
Jason Chhen,
Shuqin Liu,
Haiyan Sui,
Xiaoying Bian,
Xiaoyi Wei,
Jan Rybniker,
Uli Kazmaier,
Chengzhang Fu
Bioactivity-guided isolation of crossiguanipyrazines (CGPs) from Crossiella cryophila DSM 44230 revealed potent activity against Gram-positive bacteria, including Mycobacterium tuberculosis, with no detected cytotoxicity. Stable isotope-labeling studies uncovered their distinctive biosynthetic origin, and the first total synthesis of CGP I was accomplished, enabling future optimization.
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains one of the most devastating infectious diseases, with rising antimicrobial resistance exacerbating the urgent need for new therapeutic agents. Here, we report the discovery of crossiguanipyrazines A-I, a rare family of potent anti-TB alkylpyrazines from the underexplored actinobacterium Crossiella cryophila DSM 44230. Crossiguanipyrazines (CGPs) feature an unusual 3-methoxyl-2,5,6-trialkyl-pyrazine scaffold with variable hydroxylation and N-prenylation. The stereochemistry of CGPs A-G was determined by Mosher's analysis and electronic circular dichroism spectroscopy. Stable isotope-labeling revealed a unique biosynthetic origin from arginine and acetate. Inhibition with a cytochrome P450 inhibitor suppressed hydroxylation, while feeding experiments with stable isotope-labeled CGP I demonstrated its role as a precursor for other CGPs, implicating P450 enzymes in CGP diversification. CGPs C and H exhibited potent anti-TB activity in the low micromolar range without mammalian cell cytotoxicity, unlike previously reported cytotoxic trialkylpyrazine-type natural products. Structure-activity relationship (SAR) studies highlighted the critical roles of hydroxylation and N-prenylation in modulating biological activity. Furthermore, we achieved the first total synthesis of CGP I, which validated the chemical structure and provided a foundation for further optimization of this compound class. These findings suggest that CGPs can serve as useful starting points for anti-TB drug development.
10 Nov 18:30
by Kevin C. Catalfano, Bradley M. Keegan, and Brian S. J. Blagg

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.5c00592
10 Nov 18:24
by Rachel P.M. Abrams, Rebecca G. Donahue, Jessica Ma, Ying Mao, Morgan E. Diolaiti, Alan Ashworth
Abrams et al. used circular permutation to develop a reversible FRET-based cysteine sensor. Biochemical and cell-based experiments established the sensor’s sensitivity and selectivity for cysteine. High-throughput phenotypic screens identified compounds that modulate cysteine levels, establishing the sensor as a valuable tool for studying cellular cysteine regulation.
07 Nov 20:33
by Xiaofei Qin
PLoS One. 2025 Nov 5;20(11):e0334632. doi: 10.1371/journal.pone.0334632. eCollection 2025.
ABSTRACT
Histone deacetylases (HDACs) mediate the removal of acetyl groups from lysine residues in both histone and non-histone proteins, and have been regarded as promising targets for drug discovery. As a central member of HDAC family, HDAC1 has been found to be closely linked to the occurrence and development of prostate cancer. In this study, we designed and synthesized a new series of 3-phenylisoxazole HDAC1 inhibitors based on the hit 7, identified by in-house compound library screening. The structure-activity relationship studies (SARs) indicated that the R1 position was relatively tolerated for activity. The linker length at R2 exerted a significant influence on activity with the relative orders of butyl > propyl > ethyl > methyl. Among synthetic 16 compounds, compound 17 indicated the strongest HDAC1 inhibitory effect with the inhibition rate of 86.78% at the concentration of 1000 nM. In addition, derivative 17 could not only well occupy the active pocket of HDAC1, but also showed favorable drug-like properties. More importantly, molecule 17 exerted potent anti-proliferative activity on prostate cancer PC3 cells with the IC50 value of 5.82 μM, and had no significant toxicity against normal prostate WPMY-1 cells. Collectively, these findings validate phenylisoxazole derivative 17 as a promising lead compound for further optimization and development.
PMID:41191566 | PMC:PMC12588503 | DOI:10.1371/journal.pone.0334632
07 Nov 19:20
by Yi Gan, Yumei Zeng, Haojie Guan, Wenjun Li, Alex Shaginian, Jin Li, Sen Gao, and Guansai Liu

Bioconjugate Chemistry
DOI: 10.1021/acs.bioconjchem.5c00455
07 Nov 14:50
by Rong ChangHann X. TuHongyu MaNeel S. JoshiaDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115bDepartment of Chemistry, Tsinghua University, Beijing 100084, ChinacDepartment of Bioengineering, Northeastern University, Boston, MA 02115
Proceedings of the National Academy of Sciences, Volume 122, Issue 44, November 2025.
SignificanceSelf-organization is a defining feature of living systems, yet remains challenging to engineer in synthetic biological materials. Our intrinsically disordered protein display platform (iDP2) platform enables programmable control over cell–cell ...
07 Nov 14:48
by Yu Yan, Kai Zhao, Shan-Shan Pan, Yu-Liang Sun, Zhi-Yong Rao, and Xian-Zheng Zhang

Journal of the American Chemical Society
DOI: 10.1021/jacs.5c13804
06 Nov 16:00
by Dany Pechalrieu, Veronique Nogueira, Nan Qiu, Brittney Racioppo, Daniel Abegg, Nissim Hay, and Alexander Adibekian

Journal of the American Chemical Society
DOI: 10.1021/jacs.5c16611
05 Nov 23:00
by Agnese M. Nicoli
Nature Chemical Biology, Published online: 04 November 2025; doi:10.1038/s41589-025-02038-4
Performing live-cell microscopy experiments with high spatial and temporal resolution requires fluorophores with highly optimized properties. This Review examines the progress in developing synthetic small-molecule fluorophores and how these in combination with innovative labeling strategies can advance chemical biology.
05 Nov 22:54
by Elisabeth Strunk,
Alfred Lobert,
Tatiana Khorovich,
Katia M. Guzman Lucio,
René Richarz,
Maximilian Hohmann,
Paul M. D'Agostino,
Tobias A. M. Gulder
The complete biosynthetic pathway of the biphenomycin antibiotics is elucidated, revealing a unique enzymatic machinery featuring a bifunctional MNIO, a regioselective arginase, a B12-dependent rSAM for C,C coupling, hydroxylation enzymology, and a metalloprotease with dual-specificity. These findings uncover new enzyme functions in RiPP biosynthesis and establish biocatalytic tools for future antibiotic discovery and engineering.
Abstract
Peptide natural products are important molecules for the development of efficient drugs for human health applications. The biphenomycins are bacterial macrocyclic peptides characterized by unique ortho-tyrosine (oTyr) residues connected by biaryl linkages. Biphenomycins possess potent antibacterial activity against Gram-positive pathogens at low doses with no eukaryotic toxicity. Despite their initial discovery in 1967, their biosynthetic pathway has remained elusive. Within this work, we identified the ribosomal biosynthetic origin of biphenomycins and elucidated all enzymatic maturation steps by in-depth functional characterization in vivo and in vitro. Key steps include selective ortho-hydroxylation events at two phenyl alanine residues catalyzed by a bifunctional multinuclear nonheme iron-dependent oxidase yielding the oTyr functionalities, biaryl cross coupling by a B12-dependent radical SAM enzyme, amino acid side-chain modifications by a highly regioselective arginase and by dedicated hydroxylases, as well as a stepwise proteolytic processing by a TldD-type but self-sufficient protease. These findings clarify the molecular basis of biphenomycin assembly, reveal unprecedented enzymatic dual functions, and provide the foundation for the targeted discovery of novel biphenomycins and for the development of bioengineering strategies to enhance yields and develop antibiotics with further increased potency, addressing the urgent need for new antimicrobial agents.
05 Nov 22:54
by Wenhui Gao,
Chuangchuang Zhang,
Xiaoyuan Yang,
Yingchun Liu,
Yao Wang,
Mengqiao Zhao,
Xiao‐Xia Xia,
Wei Huang,
Xuelin Xia,
Deyue Yan
Benefiting from multivalent interactions, the binding of the bivalent AAA-PE24 molecule to the HER2 (or EGFR) target can cooperatively facilitate its binding to the EGFR (or HER2) target, thereby enhancing the affinity and contact between the drug and targets. This, in turn, promotes proximity-enabled sulfur fluoride exchange (SuFEx) reactions with the target proteins, significantly improving the covalent crosslinking efficiency of the protein drug.
Abstract
The integration of sulfur fluoride exchange (SuFEx) chemistry into proteins is significantly advancing their applications in biological fields. However, its suboptimal reaction rates in proteins limit the effectiveness of covalent crosslinking. In this study, we develop a bivalent affinity protein drug by chemically coupling maleimide-substituted aryl fluorosulfate (MFS) linkers to a dual-targeting affinity protein drug that can covalently target both HER2 and EGFR. Benefiting from the HER2/EGFR ligand-assisted multivalent interactions, the obtained bivalent affinity protein drug with two MFS warheads exhibits an enhancement of covalent cross-link performance, which is 440% and 630% higher than that of monovalent ones. Generally, the bivalent affinity protein drug achieves over 80% covalent binding efficiency to its targets within 12 h and ultimately achieves 290% to 340% higher intracellular uptake and 360% to 460% longer tumor retention compared with that of monovalent or non-covalent control. Consequently, this bivalent affinity protein drug showed extraordinary antitumor efficacy in HER2/EGFR-positive pancreatic tumor models with a tumor inhibition rate (TIR) of 90.4%, which was significantly higher than that of monovalent or non-covalent ones (28.4% to 66.9%). In brief, this SuFEx-engineered, bivalent targeted strategy provides a promising platform for the design of covalent protein drugs in the future.
05 Nov 19:02
by Masakazu Kobayashi
Nature Chemistry, Published online: 04 November 2025; doi:10.1038/s41557-025-01979-6
Non-ribosomal peptide cyclases that catalyse head-to-tail macrocyclization are repurposed here to enable regioselective macrocyclization of branched peptides with multiple nucleophiles, affording lariat-shaped peptides with various sequences and ring sizes. Coupled with subsequent site-selective acylation chemistry, this chemoenzymatic approach facilitates modular access to structurally diverse lariat lipopeptides.
05 Nov 14:22
by Agnese M. Nicoli
Nature Chemical Biology, Published online: 04 November 2025; doi:10.1038/s41589-025-02038-4
Performing live-cell microscopy experiments with high spatial and temporal resolution requires fluorophores with highly optimized properties. This Review examines the progress in developing synthetic small-molecule fluorophores and how these in combination with innovative labeling strategies can advance chemical biology.
05 Nov 14:19
by Maxwell Sigal, Markus Egner, Chikako Okada, Daniel Merk, Toru Sengoku, Takayuki Katoh, and Hiroaki Suga

Journal of the American Chemical Society
DOI: 10.1021/jacs.5c13803
04 Nov 20:53
by Morgan S A Gilman
Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2514198122. doi: 10.1073/pnas.2514198122. Epub 2025 Nov 3.
ABSTRACT
The peptidoglycan (PG) cell wall is critical for bacterial growth and survival and is a primary antibiotic target. MreD is an essential accessory factor of the Rod complex, which carries out PG synthesis during elongation, yet little is known about how MreD facilitates this process. Here, we present the cryoelectron microscopy structure of Thermus thermophilus MreD in complex with another essential Rod complex component, MreC. The structure reveals that a periplasmic-facing pocket of MreD interacts with multiple membrane-proximal regions of MreC. We use single-molecule FRET to show that MreD controls the conformation of MreC through these contacts, inducing a state primed for Rod complex activation. Using Escherichia coli as a model, we demonstrate that disrupting these interactions abolishes Rod complex activity in vivo. Our findings reveal the role of MreD in bacterial cell shape determination and highlight its potential as an antibiotic target.
PMID:41183199 | DOI:10.1073/pnas.2514198122
04 Nov 01:35
by Qi-Long Hu and Steven H. Liang

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.5c00625
03 Nov 22:38
by Arighna Sarkar
Chembiochem. 2025 Dec 11;26(24):e202500629. doi: 10.1002/cbic.202500629. Epub 2025 Nov 2.
ABSTRACT
In this work, we develop a platform for multimerizing peptides/miniproteins using various polyvalent thioester cores derived from easy-to-synthesize N-hydroxysuccinimide esters. We employed native chemical ligation to attach multiple copies of peptide/miniprotein around a fixed multi-armed thioester core in a one-pot fashion, leading to the first-generation multimers. Further, using a reverse thioether ligation strategy, we synthesized second-generation branched homo/hetero multimers. The reactions proceed under an aqueous environment that closely mimics physiological conditions, forming multimeric products with yields ranging from 30% to 90%. The general utility of this strategy is showcased by the synthesis of multimeric linear and bicyclic peptides, bicyclic peptide-cell penetrating peptide conjugates, and multimeric miniproteins which show picomolar affinity against SARS-CoV-2 receptor binding domain. We believe that this modular approach of generating multimeric molecules should find broad applicability in peptide chemistry and chemical biology.
PMID:41176651 | DOI:10.1002/cbic.202500629
03 Nov 22:30
by Xu-Wen Gui
Biology (Basel). 2025 Oct 14;14(10):1414. doi: 10.3390/biology14101414.
ABSTRACT
Mycobacterium tuberculosis (M. tuberculosis) has developed some strategies to evade host immune responses through ubiquitination, thereby facilitating persistent mycobacterial infection. The Rv3717 protein has been identified as a peptidoglycan (PG) amidase that contributes to mycobacterial survival, but its exact mechanism is still unclear. The findings of this study indicate that Rv3717 inhibits mycobacterial clearance within pulmonary epithelial cells. To elucidate the molecular mechanisms by which Rv3717 facilitates persistent infection, we identified intracellular candidates interacting with Rv3717 using co-immunoprecipitation (Co-IP) combined with liquid chromatography-mass spectrometry (LC-MS/MS). The unique proteins are categorized into three functional networks: mRNA splicing, the immune system process, and the translation process through Protein-Protein Interaction (PPI) analysis. The candidate interacting proteins of Rv3717 are involved in interleukin-2 enhancer-binding factor 2 (ILF2) and TAF15, as well as the polyubiquitin chain (UBC) and E3 ubiquitin ligase TRIM21. Our results suggest that intracellular Rv3717 is likely to influence biological processes through the potential interacting proteins. Our findings confirmed that Rv3717 interacted with interleukin enhancer-binding factor 2 (ILF2) through Co-IP and immunofluorescence assays. Furthermore, Rv3717 was verified to bind with ubiquitin and be degraded through the proteasome system. More importantly, the ubiquitination of Rv3717 accelerated the proteasomal degradation of ILF2 and downregulated the expression of IL-2. This study is the first to propose that the ubiquitination of the mycobacterial membrane vesicle-associated protein Rv3717 facilitates the proteasomal degradation of ILF2, resulting in the downregulation of IL-2 expression. Overall, the role of intracellular Rv3717 in promoting mycobacterial survival is associated with its ubiquitination and the proteasomal degradation of ILF2.
PMID:41154817 | PMC:PMC12561918 | DOI:10.3390/biology14101414
02 Nov 19:49
by Murat Bozdag, Nabil Mroweh, Alessia Raucci, Andrea Angeli, Silvia Peppicelli, Alessio Biagioni, Lido Calorini, Daniela Trisciuoglio, Rino Ragno, Roberta Astolfi, Lidia Giuliani, Clemens Zwergel, Sergio Valente, Elena Andreucci, Fabrizio Carta, Antonello Mai, and Claudiu T. Supuran

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.5c01788
02 Nov 19:31
by Yu Ma, Xiaoyang Liu, Qiaochu Jiang, Hai-Dong Xu, Guowei Liang, Wenjun Zhan, Xianbao Sun, and Gaolin Liang

Journal of the American Chemical Society
DOI: 10.1021/jacs.5c13182
31 Oct 17:38
by Hang Xu
JACS Au. 2025 Oct 1;5(10):4893-4903. doi: 10.1021/jacsau.5c00832. eCollection 2025 Oct 27.
ABSTRACT
The inverse electron demand Diels-Alder (IEDDA) click reaction of tetrazine (Tz) with trans-cyclooctene (TCO), which takes place at an exceptionally high rate, has excellent orthogonality and biocompatibility. As a result, the unrivaled capacity of this process enables it to serve as a viable chemical tool for protein modification even in humans. However, the utility of this click reaction is impeded by the limited number of practical methods for the incorporation of the Tz moiety into proteins. Herein, we describe the simple dual-functional Tz-substituted allyl acetate reagent, TzAA, that targets bis-thiol moieties for direct, site-selective installation of a Tz group into native peptides and proteins. In addition to functioning as an IEDDA-based click reaction center, the Tz moiety in TzAA activates double Michael cascade reactions of the allylic acetate moiety with bis-thiols or from disulfide derivatives. We demonstrated the versatility and generality of bioconjugation reactions of TzAA that produce well-defined peptide and protein conjugates without compromising biological activities. The Tz-conjugates serve as a versatile handle for facile click reactions to introduce various functionalities. Moreover, the reagent is validated as a versatile linker for the synthesis of stapled peptides with protecting-group-free peptides. As shown, the Tz-derived cyclic peptides offer unrivaled capacity for selective targeting and delivery of TCO-caged prodrugs with reduced side effects. Collectively, the results of this investigation demonstrate that the probe with its unrivaled dual bioconjugation and click capacity, operational simplicity, and high labeling efficiency will offer a powerful chemical tool for direct, site-selective peptide/protein modification.
PMID:41169594 | PMC:PMC12569695 | DOI:10.1021/jacsau.5c00832
31 Oct 17:38
by Andrea Sarahi Medina-Rivero, Sarah Ratkovich-Gonzalez, Mariana del Rocio Ruiz-Briseño, and Vida Celeste Rosas-González

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.5c00385
31 Oct 17:38
by Rahul Maitra, Deepanshi Saxena, Swechchha Singh, Arya A, Agnideepta Majumder, S. Janani, Arunava Dasgupta, and Sidharth Chopra

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.5c00570
31 Oct 17:35
by Xinshuang Zhang, Dong Luo, Rongqing Xia, Kangxiu Wu, Xueyi Li, Jingxian Chen, Huosheng Zhou, Jie Hu, Songyin Huang, Shuyi Jia, Chengrun Li, Yan Bao, Houbing Zhang, Liping Zhao, Lu Cai, and Menghua Xiong

Journal of the American Chemical Society
DOI: 10.1021/jacs.5c14236
30 Oct 14:34
by Jingnan Chen, Qikai Zhang, Rui Mo, Qi Deng, Binbin Hu, and Suwei Dong

Journal of the American Chemical Society
DOI: 10.1021/jacs.5c11038
30 Oct 14:24
by Patrick R. A. Zanon
Nature Chemistry, Published online: 30 October 2025; doi:10.1038/s41557-025-01902-z
Covalent inhibitors are powerful entities in drug discovery. Now the amino acid selectivity and reactivity of a diverse electrophile library have been assessed proteome-wide using an unbiased workflow. This comparative analysis and the probes described could help guide the discovery and design of covalent ligands targeting residues beyond cysteine.
30 Oct 14:23
by Jeyun Jo
Nature Chemistry, Published online: 30 October 2025; doi:10.1038/s41557-025-01906-9
In the growing field of chemical proteomics, there is a need for general methods to map the reactivity profiles of covalent probes in complex proteomes. Now, a completely unbiased proteomic workflow has been developed that enables global characterization of the amino acid residues, chemically labelled by reactive electrophilic probes.
30 Oct 14:18
by Yu Du
Adv Sci (Weinh). 2025 Oct 27:e14408. doi: 10.1002/advs.202514408. Online ahead of print.
ABSTRACT
Lysozymes are well-known for their ability to cleave bacterial peptidoglycan, but their potential to hydrolyze viral components as a form of antiviral defense remains poorly understood. This study demonstrates that insect i-type lysozymes (Lyz-I1), regulated by the Toll signaling pathway, function as proteases that directly cleave viral proteins. Structural and functional analyses reveal that the catalytic dyad Glu34/Asp50 in leafhopper Lyz-I1, while retaining its essential role in bacterial peptidoglycan hydrolysis, also mediates specific binding to Lys180 on the viroplasm protein Pns9 of rice gall dwarf virus (RGDV). This interaction catalyzes the cleavage of the adjacent peptide bond of Lys180, leading to Pns9 degradation, which disrupts viroplasm assembly and inhibits viral replication. Notably, this proteolytic antiviral mechanism of Lyz-I1 shows evolutionary conservation across major rice reoviruses and their respective leafhopper or planthopper vectors. Additionally, leafhopper Lyz-I1 undergoes liquid-liquid phase separation, forming biomolecular condensates that concentrate Pns9 and enhance proteolytic efficiency. Critically, exogenous application of Lyz-I1 not only effectively reduces viral titer and disease symptoms in RGDV-infected rice plants but also induces plant immune defense. Consequently, this work provides the evidence that lysozymes can function as specific antiviral proteases, establishing a foundation for innovative control strategies against viral diseases.
PMID:41144906 | DOI:10.1002/advs.202514408
29 Oct 18:08
by Yishu Bao and Jiang Xia

JACS Au
DOI: 10.1021/jacsau.5c01164